Labcorp Holdings Inc.

LH Healthcare Diagnostics & Research

Labcorp Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.0 billion, up 7.25% from fiscal 2024. In the quarter to June 2026, revenue grew 5.78%, EPS grew 28.4%, free cash flow fell 42.0% and total debt rose 15.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years, revenue growth for three.

318.66 6.41 −1.97%
Market cap
$26.4B
P/E
26.2×
Fwd P/E
19.0×
Dividend yield
0.90%
F-score
8/9
Altman Z
3.02
Beneish M
−2.55
Dividend safety
74/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
23.01 23.49 23.80 27.98

+8 more quarters

P/S ratio
1.59 1.55 1.50 1.73
P/FCF ratio
22.16 17.41 19.40 19.12
P/Operating CF
51.35 114.67 33.98 61.61
P/B ratio
2.66 2.52 2.42 2.74
EV/Sales
2.00 1.90 1.83 2.06
EV/EBITDA
13.07 12.63 12.34 14.12
EV/FCF
27.76 21.31 23.69 22.77
Current Ratio
1.80 1.73 1.42 1.55
Net Debt/EBITDA
9.16 8.87 10.48 8.01
Debt/Equity
0.69 0.68 0.60 0.59
Earnings Yield
4.35% 4.26% 4.20% 3.57%
Free Cash Flow Yield
4.51% 5.74% 5.15% 5.23%
Free Cash Flow per Share
3.87 0.95 5.95 3.39
Book value per Share
105.35 106.06 103.60 104.66
Free Cash Flow
315.80 78.30 494.80 281.60
EV/EBIT
19.15 18.67 18.41 21.30
Other line items

Show all line items

Columns are period end dates